Studie GAPSID – Jak analogy GLP-1 zabraňují diabetu vyvolanému steroidy
Jak analogy GLP-1 zabraňují diabetu vyvolanému steroidy
TITLE: How GLP-1 Analogues prevent steroid-induced diabetes (The GAPSID Study)
DESIGN: A double-blind study evaluating how GLP-1 analogues, compared with metformin, prevent hyperglycaemia in response to a 7-day course of dexamethasone (DEX) 6 mg once daily. This is a mechanistic experimental medicine study.
AIMS: To evaluate the mechanisms by which GLP-1 analogues reduce steroid-induced hyperglycaemia compared to metformin.
OUTCOME MEASURES:
- Primary: Glucose tolerance in response to standardised mixed meal test (MMT) lasting for 240 minutes, measured in all participants at baseline and on day 7 DEX.
- Secondary: Indices of insulin resistance (M-value), beta-cell function (acute insulin response to glucose) and disposition, as measured by a combined IV glucose tolerance test and hyperinsulinaemic-euglycaemic clamp, performed at baseline and on day 7 DEX.
- Exploratory: Tissue specific changes in adipose AMPK determined from adipose and muscle biopsies, taken from a subset of approximately 8 individuals in each group.
ELIGIBILITY: People living with pre-diabetes or lifestyle controlled diabetes
STUDY DURATION: This study will take place over 3 weeks for each partcipant. Study procedures include 10 days of baseline continuous glucose monitoring (CGM) followed by 7 days of dexamethasone with GLP-1, metformin or placebo. Participants will attend a follow-up visit 3-5 days after completing the 7-day course of study drug. The study will run over a period of 3 years.
ANTICIPATED IMPACT: Mechanistic evidence for the use of GLP-1 analogues, compared with metformin, in the treatment of steroid-induced diabetes.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Katharine Lazarus, MBChB, BSc
- Telefonní číslo: 07555717544
- E-mail: k.lazarus@imperial.ac.uk
Studijní místa
-
-
-
London, Spojené království
- Nábor
- Imperial College Healthcare NHS Trust
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults ≥ 18 years;
- Male or female;
- Pre-diabetes (HbA1c ≥42 and <47 mmol/mol, or lifestyle-controlled diabetes (HbA1c ≥48 and ≤52 mmol/mol); measurements within range on two separate occasions ≥90 days apart)
- Body mass index ≥22.5 kg/m2
Exclusion Criteria:
- Prior treatment with any diabetes medication within 90 days;
- Current or planned pregnancy, or current breastfeeding;
- Previous treatment with GC (topical, oral, injected) within 30 days or 90 days for extended-release injected GCs (e.g. Depo-Medrone);
- Continuing requirement for GC treatment (e.g. for steroid replacement, chronic inflammatory or immunological condition);
- Treatment with medications altering DEX pharmacokinetics (e.g. phenytoin, carbamazepine, ritonavir).
- History of pancreatitis, renal disease (eGFR <30), severe hepatic impairment, gallbladder disorders, or GI disease (e.g. IBD), heart failure, history of medullary thyroid cancer (MTC), or previous skin reactions.
- History of bleeding disorders of anticoagulant therapies (exclusion from the biopsy substudy only)
- History of giving blood or having taken part in another non-related study in the last three months
- History of any other medical, psychological condition, or use of any medications, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Základní věda
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Once daily semaglutide
Once daily semaglutide 3 mg (uptitrated to 3 mg twice daily after two days). |
Oral semaglutide 3mg once uptitrated to twice daily |
|
Aktivní komparátor: - Metformin
Metformin modified release tablets (500mg once daily for the first two days, then 500 mg twice daily). |
Metformin modified release tablets 500mg once daily uptitrated to twice daily). |
|
Komparátor placeba: Placebo
Placebo tablets |
Placebo tablets |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Difference in Glucose tolerance
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Glucose tolerance as measured by glucose area under the curve (AUC), in response to standardised mixed meal test (MMT) lasting for 240 minutes. This will be measured in all participants at baseline and at the end of the study medication period (after 7 days of dexamethasone and study medication). |
Through study completion, on day 7 dexamethasone and study medication
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Difference in insulin secretion
Časové okno: Day 6 of dexamethasone and study medication
|
This will be measured by the acute insulin response to glucose based on the incremental AUC for insulin during the first 10 minutes of an IVGTT and the second phase insulin response based on incremental AUC for insulin during +10 to +60 minutes. This will be measured in a subset of patients (10 from each randomisation group), performed at baseline and on day 6 of dexamethasone and study medication |
Day 6 of dexamethasone and study medication
|
|
Difference in insulin sensitivity
Časové okno: Day 6
|
This will be measured by the M value, based on the glucose infusion rate during the last 60 minutes of a hyperinsulinaemic-euglycaemic clamp. This will be measured in a subset of patients (10 from each randomisation group), performed at baseline and on day 6 of dexamethasone and study medication |
Day 6
|
|
Difference in insulin sensitivity
Časové okno: Day 6
|
This will be measured by the M/I index, calculated by the M value divided by the mean steady state insulin levels during the last 60 minutes of a hyperinsulinaemic-euglycaemic clamp. This will be measured in a subset of patients (10 from each randomisation group), performed at baseline and on day 6 of dexamethasone and study medication |
Day 6
|
|
Difference in insulin sensitivity
Časové okno: Day 6
|
This will be measured by the disposition index. This will be calculated as the product of the AIRg and M value during the combined IVGTT and hyperinsulinaemic-euglycaemic clamp. This will be measured in a subset of patients (10 from each randomisation group), performed at baseline and on day 6 of dexamethasone and study medication. |
Day 6
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean glucose and glycaemic variation by continuous glucose monitoring (CGM), using a validated blinded system (Dexcom G7).
Časové okno: Through study completion
|
A baseline recording will be made for 10 days prior to DEX. A second 10-day recording will be made covering the 7 days of DEX and for 3 days after. |
Through study completion
|
|
Changes in fasting gut hormones
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Fasting glucose will be measured at baseline and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Changes in fasting gut hormones
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Fasting insulin and c-peptide levels will be measured at baseline and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Changes in fasting gut hormones
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Fasting glucagon levels will be measured at baseline and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Changes in fasting lipid profile
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Fasting lipid profiles will be measured at baseline and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Changes in post prandial gut hormones
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Post prandial insulin and c-peptide levels will be measured during the mixed meal test, performed at baseline and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Changes in post prandial gut hormones
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Post prandial glucagon levels will be measured during the mixed meal test, performed at baseline and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Changes in anthropometrics
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Anthropometric measurements of height and weight will be combined to report BMI kg/m2 before and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Changes in anthropometrics
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
Measurements of hip and waist circumference will be combined to calculate the waist:hip ratio before and after a 7-day course of DEX and treatment intervention. |
Through study completion, on day 7 dexamethasone and study medication
|
|
Tissue specific changes in AMPK determined from adipose and muscle biopsies
Časové okno: Through study completion, on day 7 dexamethasone and study medication
|
This will be taken from a subset of approximately 8 individuals in each group prior to, and at the end of a 7 day course of DEX. Depending on emerging data and participant uptake, this may be subject to change. |
Through study completion, on day 7 dexamethasone and study medication
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Karim Meeran, Imperial College London
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 22HH8018
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .